Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAME-specific B7-H3 CAR T cells
- Development stage
- Preclinical
- Lead developer
- Immatics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral, Intracerebroventricular, Intracranial, Intraperitoneal
01
Overview
**PRAME-specific B7-H3 CAR T cells** are an investigational, allogeneic donor-derived cellular immunotherapy approach for **diffuse midline glioma**. The product concept uses PRAME-specific T cells from healthy donors that are genetically modified to express a CAR directed against the surface antigen B7-H3, combining native PRAME-directed T-cell reactivity with CAR-mediated B7-H3 recognition. In reported preclinical experiments, CAR-transduced PRAME-specific T cells showed enhanced activity against partially HLA-matched diffuse midline glioma cells, although cytotoxicity was not significantly greater than that of B7-H3 CAR-transduced non-specific T cells. The published work describes a research-stage platform rather than a named clinical product or registered therapeutic asset. ([jitc.bmj.com](https://jitc.bmj.com/content/13/Suppl_2/A355))
- Other names
- B7-H3 CAR PRAME-specific T cellsB-7-H3 CAR PRAME-specific T cellsB 7-H3 CAR PRAME-specific T cellsPRAME-specific B7-H3 CAR T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on PRAME-specific B7-H3 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME-specific B7-H3 CAR T cells.